Blueberry Effects on Dark Vision and Glare Recovery

September 11, 2013 updated by: Wilhelmina Kalt, Atlantic Food and Horticulture Research Center

Placebo-controlled Cross-over Studies Examining Blueberries Effects on Dark Vision and Recovery After Photo-bleaching

Clinical evidence for effects of plant anthocyanins on vision, and particularly night vision is controversial. Two clinical trials were conducted to investigate whether blueberry juice consumption affected visual dark adaptation, functional night vision, and recovery after photo-bleaching of the retina. One trial (S2) employed a 3 week intervention and washout period, and two doses of blueberries plus a placebo. The other trial (L1) employed a 12 week intervention plus an 8 week washout and tested one blueberry juice dose against a juice placebo.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Vision Tests: 1. Dark adaptometry, 2. scotopic visual acuity, 3. scotopic contrast sensitivity, 4. rod/cone conversion, 5. recovery after retinal photobleaching

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
72

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Nova Scotia
      • Kentville, Nova Scotia, Canada, B4N1J5
        • Atlantic Food and Horicultural Research Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

31 years to 61 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • visual acuity better than 6/7.5 on EDTRS acuity chart at 2.5m
  • visual contrast sensitivity within normal range at 2.5m as tested on Visteck 3000
  • stereo acuity better than 80 seconds of arc on Frisby stereoacuity test
  • no ocular history other than refractive glasses
  • no family history of eye disease

Exclusion Criteria:

  • family history of retinal degeneration, glaucoma, diabetes, hypertension, cataract, or amblyopia (dimness in vision).
  • evidence in subject (upon examination) of amblyopia (dimness in vision), manifest strabismus (unable to focus both eyes on one spot), or anisotropia (non-uniform responsiveness between both eyes).
  • intraocular pressure above 21mmHG from an average of three measures using Mentor tonopen-XL

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Non-Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Blueberry Juice
Commercially prepared single strength blueberry juice which was composed of a 50:50 blend of two highbush blueberry species (Vaccinium corymbosum L. 'Rubel' and V. ashei Reade 'TifBlue'). Volunteers consumed 300 mls of juice/day (247-271 mg anthocyanins (as C3G) daily) while on this intervention, for either 3 weeks (Blueberry Juice S2) or 12 weeks (Blueberry Juice L1).
Dietary supplement: Blueberry Juice S2
Blueberry Juice S2 was commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars. Colorimetric analysis showed that S2 juice contained 6.04 (SD=0.20) mg anthocyanins (C3G) eq/g dry mass.
Other Names:
  • Single-strength blueberry juice, commercially prepared
Dietary supplement: Blueberry Juice L1
Blueberry Juice L1 was commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars. Colorimetric analysis showed that L1 juice contained 6.83 (SD=0.20) mg cyanidin-3-glucoside equivalents (C3GE)/g dry mass at the start of the study, declining to 5.52 (SD=0.09) mg C3GE/g dry mass after 3 months refrigerated storage.
Other Names:
  • single strength blueberry juice, commercially prepared
Active Comparator: Blueberry Capsules
Commercially prepared single strength blueberry juice which was composed of a 50:50 blend of two highbush blueberry species (Vaccinium corymbosum L. 'Rubel' and V. ashei Reade 'TifBlue')was freeze dried to a powder and encapsulated in gelatin capsules (Blueberry Capsules S2). Volunteers consumed 3 capsules/daily (7.11mg anthocyanin (as C3G eq) for 3 weeks.
Dietary supplement: Blueberry Capsules S2
Commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars was freeze dried then powdered and encapsulated in gelatin capsules. Colorimetric analysis indicated an anthocyanin concentration in the powder of 2.37(SD=0.18) mg C3G eq per capsule.
Other Names:
  • freeze-dried blueberry juice powder
Placebo Comparator: Placebo
Volunteers consumed in S2 three placebo capsules daily for 3 weeks. In L1 volunteers consumed 300ml placebo juice for twelve weeks. Placebo products contained no anthocyanins.
Dietary supplement: Placebo Capsule S2
Placebo Capsule S2 (containing no anthocyanins) were prepared by freeze drying red beets and grinding them to fine powder before encapsulating in gelatine capsules. Red beets do not contain anthocyanins.
Other Names:
  • Red beet powder
Dietary supplement: Placebo Juice L1
Placebo juice was prepared from water, sugars, citric acid, sodium citrate, and artificial colors and flavours, then pasteurized. The placebo juice contains no anthocyanins.
No Intervention: Washout (S2 and L1)
Washout periods involved no study products. Washout was 3 weeks in S2 and or 8 weeks (L1) in duration.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Rate of vision adaptation to low light after blueberry juice and placebo ingestion for 3 weeks (S2).
Time Frame: Pre-intervention, and changes after 3 weeks of intervention, and again after 3 weeks of washout
Effect of blueberry products and placebo on the rate of vision adaptation to low light. The rate of vision adaptation is measured by lowest perceptible light intensity after 30 min of darkness (dark threshold); time to reach dark threshold (min); time to reach rod/cone transition (min) [Time Frame: Pre-intervention, after 3 weeks intervention, again after a 3 week washout.] [Designated as safety issue: No]
Pre-intervention, and changes after 3 weeks of intervention, and again after 3 weeks of washout
Rate of vision adaptation to low light after ingestion of blueberry juice and placebo for 12 weeks (L1).
Time Frame: Preintervention, and changes after 8 and 12 weeks of intervention and after 4 and 8 weeks of washout
Effect of blueberry products and placebo on the rate of vision adaptation to low light. The rate of vision adaptation is measured by lowest perceptible light intensity after 30 min of darkness (dark threshold); time to reach dark threshold (min); time to reach rod/cone transition (min) [Time Frame: Pre-intervention, after 8 and 12 weeks intervention, and again after 4 and 8 weeks washout] [Designated as safety issue: No]
Preintervention, and changes after 8 and 12 weeks of intervention and after 4 and 8 weeks of washout

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Rate of recovery of visual acuity after retinal photostress (S2).
Time Frame: Pre-intervention testing and testing for changes after 3 weeks of intervention and 3 weeks of washout
After dark adaptation testing (primary outcome) and contrast sensitivity and visual acuity testing (other pre-specified outcome measures), participants are subjected to photostress of the retina using bright light. The time (sec) required to recover pre-stress acuity is measured.
Pre-intervention testing and testing for changes after 3 weeks of intervention and 3 weeks of washout
Rate of recovery of visual acquity after retinal photostress (L1).
Time Frame: Pre-intervention and then testing for changes after 8 and 12 weeks of intervention and 4 and 8 weeks of washout.
After dark adaptation testing (primary outcome) and contrast sensitivity and visual acuity testing (other pre-specified outcome measures) participants are subjected to photostress of the retina using bright light. The time (sec) required to recover pre-stress acuity is measured.
Pre-intervention and then testing for changes after 8 and 12 weeks of intervention and 4 and 8 weeks of washout.

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Visual acuity and contrast sensitivity testing after dark adaptation (S2).
Time Frame: Testing preintervention and testing for changes after 3 weeks of intervention and 3 weeks of washout
After dark adaptation testing (primary outcome measure) and before measuring rate of recovery from photo stress (secondary outcome) visual acuity in darkness and contrast sensitivity in darkness was measured using defined optotypes with different degrees of crowding and contrast. Performance was defined as the number of correct answers in 12 tests of acuity and 8 tests of contrast sensitivity.
Testing preintervention and testing for changes after 3 weeks of intervention and 3 weeks of washout
Visual acuity and contrast sensitivity testing after dark adaptation (L1).
Time Frame: Testing preintervention and testing for changes after 8 & 12 weeks of intervention and 4 & 8 weeks of washout
After dark adaptation testing (primary outcome measure) and before testing rate of recovery from photo stress (secondary outcome) visual acuity in darkness and contrast sensitivity in darkness was measured using defined optotypes with different degrees of crowding and contrast. Performance was defined as the number of correct answers in 12 tests of acuity and 8 tests of contrast sensitivity.
Testing preintervention and testing for changes after 8 & 12 weeks of intervention and 4 & 8 weeks of washout

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Atlantic Food and Horticulture Research Center

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Dalhousie University
U.S. Highbush Blueberry Council

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Wilhelmina Kalt, PhD, Agriculture and Agri-Food Canada
  • Principal Investigator: Francois Tremblay, PhD, Dalhousie University and IWK Health Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 1, 2005

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 1, 2006

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 1, 2006

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 23, 2013

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 11, 2013

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 16, 2013

Study Record Updates

Last Update Posted (Estimate)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 16, 2013

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 11, 2013

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Blueberries and Vision

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings